Forecasting stroke-like episodes and outcomes in mitochondrial disease.


Journal

Brain : a journal of neurology
ISSN: 1460-2156
Titre abrégé: Brain
Pays: England
ID NLM: 0372537

Informations de publication

Date de publication:
18 04 2022
Historique:
received: 10 05 2021
revised: 16 07 2021
accepted: 06 08 2021
pubmed: 21 12 2021
medline: 21 4 2022
entrez: 20 12 2021
Statut: ppublish

Résumé

In this retrospective, multicentre, observational cohort study, we sought to determine the clinical, radiological, EEG, genetics and neuropathological characteristics of mitochondrial stroke-like episodes and to identify associated risk predictors. Between January 1998 and June 2018, we identified 111 patients with genetically determined mitochondrial disease who developed stroke-like episodes. Post-mortem cases of mitochondrial disease (n = 26) were identified from Newcastle Brain Tissue Resource. The primary outcome was to interrogate the clinico-radiopathological correlates and prognostic indicators of stroke-like episode in patients with mitochondrial encephalomyopathy, lactic acidosis and stroke-like episodes syndrome (MELAS). The secondary objective was to develop a multivariable prediction model to forecast stroke-like episode risk. The most common genetic cause of stroke-like episodes was the m.3243A>G variant in MT-TL1 (n = 66), followed by recessive pathogenic POLG variants (n = 22), and 11 other rarer pathogenic mitochondrial DNA variants (n = 23). The age of first stroke-like episode was available for 105 patients [mean (SD) age: 31.8 (16.1)]; a total of 35 patients (32%) presented with their first stroke-like episode ≥40 years of age. The median interval (interquartile range) between first and second stroke-like episodes was 1.33 (2.86) years; 43% of patients developed recurrent stroke-like episodes within 12 months. Clinico-radiological, electrophysiological and neuropathological findings of stroke-like episodes were consistent with the hallmarks of medically refractory epilepsy. Patients with POLG-related stroke-like episodes demonstrated more fulminant disease trajectories than cases of m.3243A>G and other mitochondrial DNA pathogenic variants, in terms of the frequency of refractory status epilepticus, rapidity of progression and overall mortality. In multivariate analysis, baseline factors of body mass index, age-adjusted blood m.3243A>G heteroplasmy, sensorineural hearing loss and serum lactate were significantly associated with risk of stroke-like episodes in patients with the m.3243A>G variant. These factors informed the development of a prediction model to assess the risk of developing stroke-like episodes that demonstrated good overall discrimination (area under the curve = 0.87, 95% CI 0.82-0.93; c-statistic = 0.89). Significant radiological and pathological features of neurodegeneration were more evident in patients harbouring pathogenic mtDNA variants compared with POLG: brain atrophy on cranial MRI (90% versus 44%, P < 0.001) and reduced mean brain weight (SD) [1044 g (148) versus 1304 g (142), P = 0.005]. Our findings highlight the often idiosyncratic clinical, radiological and EEG characteristics of mitochondrial stroke-like episodes. Early recognition of seizures and aggressive instigation of treatment may help circumvent or slow neuronal loss and abate increasing disease burden. The risk-prediction model for the m.3243A>G variant can help inform more tailored genetic counselling and prognostication in routine clinical practice.

Identifiants

pubmed: 34927673
pii: 6470561
doi: 10.1093/brain/awab353
pmc: PMC9014738
doi:

Substances chimiques

DNA, Mitochondrial 0

Types de publication

Journal Article Multicenter Study Observational Study Research Support, Non-U.S. Gov't

Langues

eng

Sous-ensembles de citation

IM

Pagination

542-554

Subventions

Organisme : Alzheimer's Society
ID : 181
Pays : United Kingdom
Organisme : Medical Research Council
ID : G1100540
Pays : United Kingdom
Organisme : Medical Research Council
ID : G0900652
Pays : United Kingdom
Organisme : Medical Research Council
ID : G0502157
Pays : United Kingdom
Organisme : Medical Research Council
ID : MR/S002065/1
Pays : United Kingdom
Organisme : Medical Research Council
ID : G0400074
Pays : United Kingdom
Organisme : Wellcome Trust
Pays : United Kingdom

Informations de copyright

© The Author(s) (2021). Published by Oxford University Press on behalf of the Guarantors of Brain.

Références

Ann Neurol. 1984 Oct;16(4):481-8
pubmed: 6093682
Lancet. 2018 Oct 6;392(10154):1247-1256
pubmed: 30319112
Neuropathol Appl Neurobiol. 2016 Aug;42(5):477-92
pubmed: 26337858
Nat Rev Neurosci. 2014 Jan;15(1):43-53
pubmed: 24281245
J R Soc Med. 2006 May;99(5):219-20
pubmed: 16672748
J Clin Neurophysiol. 2013 Oct;30(5):505-16
pubmed: 24084183
J Clin Neurophysiol. 2012 Oct;29(5):397-407
pubmed: 23027097
J Neurol. 2014 Mar;261(3):504-10
pubmed: 24375076
Brain. 2019 Feb 1;142(2):391-411
pubmed: 30689758
Neurology. 2006 Jun 27;66(12):1932-4
pubmed: 16801664
Brain. 2012 Jan;135(Pt 1):62-71
pubmed: 22189570
Acta Neuropathol. 2010 Jan;119(1):7-35
pubmed: 20012068
Nature. 1990 Dec 13;348(6302):651-3
pubmed: 2102678
J Neurol Neurosurg Psychiatry. 2005 Jun;76 Suppl 2:ii8-12
pubmed: 15961870
Pract Neurol. 2013 Feb;13(1):21-8
pubmed: 23315456
EMBO Mol Med. 2018 Jun;10(6):
pubmed: 29735722
Neurology. 1975 Jul;25(7):614-21
pubmed: 1171391
Brain. 1997 Oct;120 ( Pt 10):1713-21
pubmed: 9365365
Ann Neurol. 1992 Apr;31(4):391-8
pubmed: 1586140
J Neurol Neurosurg Psychiatry. 2008 Feb;79(2):209-11
pubmed: 18202211
Biochim Biophys Acta. 2012 May;1820(5):619-24
pubmed: 21443929
EBioMedicine. 2018 Apr;30:86-93
pubmed: 29506874
Clin Neurophysiol Pract. 2017 Aug 04;2:170-185
pubmed: 30214992
Lancet Neurol. 2018 Feb;17(2):143-152
pubmed: 29413315
J Bioenerg Biomembr. 2010 Dec;42(6):443-8
pubmed: 21069442
Neuropathol Appl Neurobiol. 2016 Feb;42(2):180-93
pubmed: 25786813
Brain. 2008 Mar;131(Pt 3):818-28
pubmed: 18238797
Seizure. 2016 May;38:63-7
pubmed: 27156207
Stroke. 2001 Jun;32(6):1318-22
pubmed: 11387493
Neurology. 2011 Nov 29;77(22):1965-71
pubmed: 22094475
Ann Neurol. 2016 Nov;80(5):686-692
pubmed: 27453452
Ann Neurol. 2015 May;77(5):753-9
pubmed: 25652200
J Clin Neurophysiol. 2004 Sep-Oct;21(5):307-18
pubmed: 15592005
Circulation. 2019 Mar 5;139(10):e56-e528
pubmed: 30700139
J R Coll Physicians Edinb. 2013;43(2):114-8
pubmed: 23734351
Neuropathol Appl Neurobiol. 2006 Aug;32(4):359-73
pubmed: 16866982
J Neurol. 2016 Jan;263(1):127-32
pubmed: 26530510
J Clin Endocrinol Metab. 2019 Jun 1;104(6):2057-2066
pubmed: 30423112
Neurol Genet. 2018 Mar 26;4(2):e230
pubmed: 29600276
Wellcome Open Res. 2019 Dec 13;4:201
pubmed: 32090171
J Inherit Metab Dis. 2020 Jul;43(4):726-736
pubmed: 32391929
JAMA Neurol. 2016 Oct 01;73(10):1201-1207
pubmed: 27533350
Epilepsia. 2018 Oct;59 Suppl 2:120-127
pubmed: 30129213
Brain. 2006 Jul;129(Pt 7):1674-84
pubmed: 16621917
Exp Neurol. 2013 Jun;244:67-74
pubmed: 22342991
Ann Intern Med. 2015 Jan 6;162(1):55-63
pubmed: 25560714
Neuromuscul Disord. 1992;2(2):125-35
pubmed: 1422200
Clin Anat. 2019 Nov;32(8):1053-1060
pubmed: 31376291
Am J Kidney Dis. 2017 May;69(5):555-557
pubmed: 28434521
Mayo Clin Proc. 2013 Oct;88(10):1127-40
pubmed: 24079682
Epilepsia Open. 2018 Jan 11;3(1):103-108
pubmed: 29588995
Eur J Radiol. 2013 Nov;82(11):1964-72
pubmed: 23787273
Epilepsia. 2016 Oct;57(10):1531-1545
pubmed: 27554452
Nat Rev Genet. 2005 May;6(5):389-402
pubmed: 15861210
J Med Genet. 2004 Oct;41(10):784-9
pubmed: 15466014
Brain. 2010 May;133(Pt 5):1428-37
pubmed: 20400524
Nat Rev Dis Primers. 2016 Oct 20;2:16080
pubmed: 27775730
Mol Genet Metab. 2015 Sep-Oct;116(1-2):4-12
pubmed: 26095523
Brain. 2012 Jun;135(Pt 6):1736-50
pubmed: 22577219
Arch Neurol. 2009 Jan;66(1):85-91
pubmed: 19139304
Nat Rev Neurol. 2019 Jan;15(1):40-52
pubmed: 30451971
Epilepsia. 2018 Jan;59(1):37-66
pubmed: 29247482
Neurology. 1992 Mar;42(3 Pt 1):545-50
pubmed: 1549215
Neuropathol Appl Neurobiol. 2017 Feb;43(2):102-118
pubmed: 27287935
Seizure. 2017 Nov;52:169-175
pubmed: 29054038
J Neurol Neurosurg Psychiatry. 2013 Aug;84(8):936-8
pubmed: 23355809
Arch Neurol. 2008 Mar;65(3):368-72
pubmed: 18332249

Auteurs

Yi Shiau Ng (YS)

Wellcome Centre for Mitochondrial Research, Translational and Clinical Research Institute; NIHR Newcastle Biomedical Research Centre and Campus for Ageing and Vitality, Newcastle University, Newcastle upon Tyne NE2 4HH, UK.
Directorate of Neurosciences, Royal Victoria Infirmary, The Newcastle upon Tyne Hospitals NHS Foundation Trust, Newcastle upon Tyne NE1 4LP, UK.
Department of Neurosciences, NHS Highly Specialised Service for Rare Mitochondrial Disorders, Newcastle upon Tyne NE2 4HH, UK.

Nichola Z Lax (NZ)

Wellcome Centre for Mitochondrial Research, Translational and Clinical Research Institute; NIHR Newcastle Biomedical Research Centre and Campus for Ageing and Vitality, Newcastle University, Newcastle upon Tyne NE2 4HH, UK.

Alasdair P Blain (AP)

Wellcome Centre for Mitochondrial Research, Translational and Clinical Research Institute; NIHR Newcastle Biomedical Research Centre and Campus for Ageing and Vitality, Newcastle University, Newcastle upon Tyne NE2 4HH, UK.

Daniel Erskine (D)

Wellcome Centre for Mitochondrial Research, Translational and Clinical Research Institute; NIHR Newcastle Biomedical Research Centre and Campus for Ageing and Vitality, Newcastle University, Newcastle upon Tyne NE2 4HH, UK.

Mark R Baker (MR)

Directorate of Neurosciences, Royal Victoria Infirmary, The Newcastle upon Tyne Hospitals NHS Foundation Trust, Newcastle upon Tyne NE1 4LP, UK.
Campus for Ageing and Vitality, Newcastle Brain Tissue Resource, Newcastle University, Edwardson Building, Newcastle upon Tyne NE4 5PL, UK.

Tuomo Polvikoski (T)

Campus for Ageing and Vitality, Newcastle Brain Tissue Resource, Newcastle University, Edwardson Building, Newcastle upon Tyne NE4 5PL, UK.

Rhys H Thomas (RH)

Wellcome Centre for Mitochondrial Research, Translational and Clinical Research Institute; NIHR Newcastle Biomedical Research Centre and Campus for Ageing and Vitality, Newcastle University, Newcastle upon Tyne NE2 4HH, UK.
Directorate of Neurosciences, Royal Victoria Infirmary, The Newcastle upon Tyne Hospitals NHS Foundation Trust, Newcastle upon Tyne NE1 4LP, UK.
Department of Neurosciences, NHS Highly Specialised Service for Rare Mitochondrial Disorders, Newcastle upon Tyne NE2 4HH, UK.

Christopher M Morris (CM)

Campus for Ageing and Vitality, Newcastle Brain Tissue Resource, Newcastle University, Edwardson Building, Newcastle upon Tyne NE4 5PL, UK.

Ming Lai (M)

Directorate of Neurosciences, Royal Victoria Infirmary, The Newcastle upon Tyne Hospitals NHS Foundation Trust, Newcastle upon Tyne NE1 4LP, UK.

Roger G Whittaker (RG)

Directorate of Neurosciences, Royal Victoria Infirmary, The Newcastle upon Tyne Hospitals NHS Foundation Trust, Newcastle upon Tyne NE1 4LP, UK.
Translational and Clinical Research Institute, Newcastle University, Newcastle upon Tyne NE2 4HH, UK.

Alasdair Gebbels (A)

Directorate of Neurosciences, Royal Victoria Infirmary, The Newcastle upon Tyne Hospitals NHS Foundation Trust, Newcastle upon Tyne NE1 4LP, UK.

Amy Winder (A)

Directorate of Neurosciences, Royal Victoria Infirmary, The Newcastle upon Tyne Hospitals NHS Foundation Trust, Newcastle upon Tyne NE1 4LP, UK.

Julie Hall (J)

Directorate of Neurosciences, Royal Victoria Infirmary, The Newcastle upon Tyne Hospitals NHS Foundation Trust, Newcastle upon Tyne NE1 4LP, UK.

Catherine Feeney (C)

Wellcome Centre for Mitochondrial Research, Translational and Clinical Research Institute; NIHR Newcastle Biomedical Research Centre and Campus for Ageing and Vitality, Newcastle University, Newcastle upon Tyne NE2 4HH, UK.
Directorate of Neurosciences, Royal Victoria Infirmary, The Newcastle upon Tyne Hospitals NHS Foundation Trust, Newcastle upon Tyne NE1 4LP, UK.
Department of Neurosciences, NHS Highly Specialised Service for Rare Mitochondrial Disorders, Newcastle upon Tyne NE2 4HH, UK.

Maria Elena Farrugia (ME)

Institute of Neurological Sciences, Queen Elizabeth University Hospital, Glasgow G51 4TF, UK.

Claire Hirst (C)

Trust Headquarters, One Talbot Gateway, Baglan Energy Park, Baglan, Port Talbot SA12 7BR, UK.

Mark Roberts (M)

Greater Manchester Neuroscience Centre, Salford Royal NHS Foundation Trust, Manchester Academic Health Science Centre, Salford M6 8HD, UK.

Charlotte Lawthom (C)

Aneurin Bevan Epilepsy Specialist Team, Aneurin Bevan University Health Board, Newport, NP20 2UB, UK.

Alexia Chrysostomou (A)

Wellcome Centre for Mitochondrial Research, Translational and Clinical Research Institute; NIHR Newcastle Biomedical Research Centre and Campus for Ageing and Vitality, Newcastle University, Newcastle upon Tyne NE2 4HH, UK.

Kevin Murphy (K)

Department of Neurology, Sligo University Hospital, Sligo F91 H684, Ireland.

Tracey Baird (T)

Institute of Neurological Sciences, Queen Elizabeth University Hospital, Glasgow G51 4TF, UK.

Paul Maddison (P)

Department of Neurology, Queen's Medical Centre, Nottingham NG7 2UH, UK.

Callum Duncan (C)

Department of Neurology, Aberdeen Royal Infirmary, NHS Grampian, Aberdeen AB25 2ZN, UK.

Joanna Poulton (J)

Nuffield Department of Women's and Reproductive Health, University of Oxford, Oxford OX3 9DU, UK.

Victoria Nesbitt (V)

Department of Paediatrics, Medical Sciences Division, Oxford University, Oxford OX3 9DU, UK.
Department of Paediatrics, The Children's Hospital, Oxford, OX3 9DU, UK.

Michael G Hanna (MG)

Department of Neuromuscular Diseases, University College London Queen Square Institute of Neurology and The National Hospital for Neurology and Neurosurgery, London WC1N 3BG, UK.

Robert D S Pitceathly (RDS)

Department of Neuromuscular Diseases, University College London Queen Square Institute of Neurology and The National Hospital for Neurology and Neurosurgery, London WC1N 3BG, UK.

Robert W Taylor (RW)

Wellcome Centre for Mitochondrial Research, Translational and Clinical Research Institute; NIHR Newcastle Biomedical Research Centre and Campus for Ageing and Vitality, Newcastle University, Newcastle upon Tyne NE2 4HH, UK.
Department of Neurosciences, NHS Highly Specialised Service for Rare Mitochondrial Disorders, Newcastle upon Tyne NE2 4HH, UK.

Emma L Blakely (EL)

Wellcome Centre for Mitochondrial Research, Translational and Clinical Research Institute; NIHR Newcastle Biomedical Research Centre and Campus for Ageing and Vitality, Newcastle University, Newcastle upon Tyne NE2 4HH, UK.
Department of Neurosciences, NHS Highly Specialised Service for Rare Mitochondrial Disorders, Newcastle upon Tyne NE2 4HH, UK.

Andrew M Schaefer (AM)

Wellcome Centre for Mitochondrial Research, Translational and Clinical Research Institute; NIHR Newcastle Biomedical Research Centre and Campus for Ageing and Vitality, Newcastle University, Newcastle upon Tyne NE2 4HH, UK.
Directorate of Neurosciences, Royal Victoria Infirmary, The Newcastle upon Tyne Hospitals NHS Foundation Trust, Newcastle upon Tyne NE1 4LP, UK.
Department of Neurosciences, NHS Highly Specialised Service for Rare Mitochondrial Disorders, Newcastle upon Tyne NE2 4HH, UK.

Doug M Turnbull (DM)

Wellcome Centre for Mitochondrial Research, Translational and Clinical Research Institute; NIHR Newcastle Biomedical Research Centre and Campus for Ageing and Vitality, Newcastle University, Newcastle upon Tyne NE2 4HH, UK.
Department of Neurosciences, NHS Highly Specialised Service for Rare Mitochondrial Disorders, Newcastle upon Tyne NE2 4HH, UK.

Robert McFarland (R)

Wellcome Centre for Mitochondrial Research, Translational and Clinical Research Institute; NIHR Newcastle Biomedical Research Centre and Campus for Ageing and Vitality, Newcastle University, Newcastle upon Tyne NE2 4HH, UK.
Department of Neurosciences, NHS Highly Specialised Service for Rare Mitochondrial Disorders, Newcastle upon Tyne NE2 4HH, UK.

Gráinne S Gorman (GS)

Wellcome Centre for Mitochondrial Research, Translational and Clinical Research Institute; NIHR Newcastle Biomedical Research Centre and Campus for Ageing and Vitality, Newcastle University, Newcastle upon Tyne NE2 4HH, UK.
Directorate of Neurosciences, Royal Victoria Infirmary, The Newcastle upon Tyne Hospitals NHS Foundation Trust, Newcastle upon Tyne NE1 4LP, UK.
Department of Neurosciences, NHS Highly Specialised Service for Rare Mitochondrial Disorders, Newcastle upon Tyne NE2 4HH, UK.

Articles similaires

[Redispensing of expensive oral anticancer medicines: a practical application].

Lisanne N van Merendonk, Kübra Akgöl, Bastiaan Nuijen
1.00
Humans Antineoplastic Agents Administration, Oral Drug Costs Counterfeit Drugs

Smoking Cessation and Incident Cardiovascular Disease.

Jun Hwan Cho, Seung Yong Shin, Hoseob Kim et al.
1.00
Humans Male Smoking Cessation Cardiovascular Diseases Female
Humans United States Aged Cross-Sectional Studies Medicare Part C
1.00
Humans Yoga Low Back Pain Female Male

Classifications MeSH